27 / 62
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 4, July/August 2020
AFRICA
189
19. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler
BK, Acton RT. Influence of CYP2C9 and VKORC1 on warfarin
dose, anticoagulation attainment and maintenance among European-
Americans and African-Americans.
Pharmacogenomics
2008;
9
(5):
511–526.
20. Bernaitis N, Ching CK, Chen L, Hon JS, Teo SC, Davey AK,
Anoopkumar-Dukie S. The sex, age, medical history, treatment, tobacco
use, race risk (SAMe TT2R2) score predicts warfarin control in a
Singaporean population.
J Stroke Cerebrovasc Dis
2017;
26
(1): 64–69.
21. Haas S, ten Cate H, Accetta G, Angchaisuksiri P, Bassand J-P, Camm
AJ,
et al.
Quality of vitamin K antagonist control and 1-year outcomes
in patients with atrial fibrillation: a global perspective from the
GARFIELD-AF Registry.
PloS One
2016;
11
(10): e0164076.
22. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to
determine the optimal intensity of oral anticoagulant therapy.
Thromb
Haemost
1993;
69
(3): 236–239.
23. Watkins D, Zuhlke L, Engel M, Daniels R, Francis V, Shaboodien G,
et al
. Seven key actions to eradicate rheumatic heart disease in Africa:
the Addis Ababa communiqué.
Cardiovasc J Afr
2016;
27
(3): 184–187.
24. Barth DD, Zühlke LJ, Joachim A, Hoegger T, Mayosi BM, Engel ME.
Effect of distance to health facility on the maintenance of INR thera-
peutic ranges in rheumatic heart disease patients from Cape Town: no
evidence for an association.
BMC Health Serv Res
2015;
15
: 219.
25. Population and Housing Census 2011. Analytical Report. Gaborone:
Statistics Botswana, 2014.
26. Schulman S, Kearon C. Definition of major bleeding in clinical investi-
gations of antihemostatic medicinal products in non-surgical patients.
J
Thromb Haemost
2005;
3
(4): 692–694.
27. Adams H, Bendixen BH, Kappelle LJ, Biller J, Love B, Gordon DL,
et al
. Classification of subtype of acute ischemic stroke.
Stroke
1993;
24
(1): 35–41.
28. Mori T, Asano M, Ohtake H, Bitoh A, Sekiguchi S, Matsuo Y,
et al
.
Anticoagulant therapy after prosthetic valve replacement – optimal
PT-INR in Japanese patients.
Ann Thorac Cardiovasc Surg
2002;
8
(2):
83–87.
29. Vijenthira A, Le Gal G, Castellucci LA, Carrier M. Defining time in
therapeutic range for busy clinicians: Frequency of dose changes is a
good surrogate marker to identify patients with suboptimal anticoagula-
tion with warfarin.
Thromb Res
2014;
134
(3): 584–586.
30. Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P,
et al
. Time in therapeutic range and outcomes after warfarin initiation
in newly diagnosed atrial fibrillation patients with renal dysfunction.
J
Am Heart Assoc Cardiovasc Cerebrovasc Dis
2017;
6
(3).
31. Wallvik J, Själander A, Johansson L, Bjuhr Ö, Jansson J-H. Bleeding
complications during warfarin treatment in primary healthcare centres
compared with anticoagulation clinics.
Scandinavian J Primary Health
Care
2007;
25
(2): 123–128.
32. Sudeep D, Sredhar K. The descriptive epidemiology of acute rheumatic
fever and rheumatic heart disease in low and middle-income countries.
Am J Epidemiol Infect Dis
2013;
1
: 34–40.
33. Sliwa K, Carrington M, Mayosi BM, Zigiriadis E, Mvungi R, Stewart
S. Incidence and characteristics of newly diagnosed rheumatic heart
disease in urban African adults: insights from the heart of Soweto study.
Eur Heart J
2009;
31
(6): 719–727.
34. Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of educa-
tion and self-monitoring in the management of warfarin therapy in
older patients with unstable control of anticoagulation.
Br J Haematol
2004;
126
(4): 557–564.
35. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting
quality of anticoagulation control among patients with atrial fibrillation
on warfarin: the SAMe-TT2R2 score.
Chest
2013;
144
(5): 1555–1563.
36. Kose E, Arai S, An T, Kikkawa A, Aoyama T, Matsumoto Y, Hayashi
H. Analysis of factors affecting time in therapeutic range control after
warfarin administration.
Die Pharmazie
2015;
70
(7): 494–498.